STABL — Stayble Therapeutics AB Balance Sheet
0.000.00%
- SEK20.11m
- SEK18.77m
Annual balance sheet for Stayble Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | SAS | SAS | SAS | SAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 10.9 | 37.5 | 12.8 | 14.1 | 2.19 |
Net Total Receivables | 0.274 | 0.325 | 0.318 | 0.252 | 0.128 |
Prepaid Expenses | |||||
Total Current Assets | 12.3 | 38 | 13.5 | 16.1 | 3.61 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 18 | 43.6 | 19.1 | 21.7 | 9.26 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.4 | 2.98 | 3.02 | 4.34 | 1.53 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 2.45 | 3.83 | 3.87 | 5.19 | 2.38 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 15.5 | 39.8 | 15.3 | 16.5 | 6.87 |
Total Liabilities & Shareholders' Equity | 18 | 43.6 | 19.1 | 21.7 | 9.26 |
Total Common Shares Outstanding |